


## Gartisertib

|                           |  |       |          |
|---------------------------|--|-------|----------|
| <b>Cat. No.:</b>          | HY-136270  |       |          |
| <b>CAS No.:</b>           | 1613191-99-3   |       |          |
| <b>Molecular Formula:</b> | C <sub>25</sub> H <sub>29</sub> F <sub>2</sub> N <sub>9</sub> O <sub>3</sub> |       |          |
| <b>Molecular Weight:</b>  | 541.55   |       |          |
| <b>Target:</b>            | ATM/ATR  |       |          |
| <b>Pathway:</b>           | Cell Cycle/DNA Damage; PI3K/Akt/mTOR   |       |          |
| <b>Storage:</b>           | Powder   | -20°C | 3 years  |
|                           |  | 4°C   | 2 years  |
|                           | In solvent   | -80°C | 6 months |
|                           |  | -20°C | 1 month  |



### SOLVENT & SOLUBILITY

|   |   |                          |              |           |            |
|---|---|--------------------------|--------------|-----------|------------|
| <b>In Vitro</b>   | DMSO : 25 mg/mL (46.16 mM; Need ultrasonic)   |                          |              |           |            |
|   |   | Solvent<br>Concentration | Mass<br>1 mg | 5 mg      | 10 mg      |
|   | <b>Preparing Stock Solutions</b>  | 1 mM                     | 1.8466 mL    | 9.2328 mL | 18.4655 mL |
|   |   | 5 mM                     | 0.3693 mL    | 1.8466 mL | 3.6931 mL  |
| 10 mM   |   | 0.1847 mL                | 0.9233 mL    | 1.8466 mL |            |
| Please refer to the solubility information to select the appropriate solvent. |   |                          |              |           |            |
| <b>In Vivo</b>  | 1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)<br>Solubility: ≥ 2.08 mg/mL (3.84 mM); Clear solution<br><br>2. Add each solvent one by one: 10% DMSO >> 90% corn oil<br>Solubility: 2.08 mg/mL (3.84 mM); Suspended solution; Need ultrasonic |                          |              |           |            |

### BIOLOGICAL ACTIVITY

|                                     |   |
|-------------------------------------|---|
| <b>Description</b>                  | Gartisertib (VX-803) is an ATP-competitive, orally active, and selective ATR inhibitor, with a K <sub>i</sub> of <150 pM. Gartisertib potently inhibits ATR-driven phosphorylated checkpoint kinase-1 (Chk1) phosphorylation with an IC <sub>50</sub> of 8 nM. Antitumor activity <sup>[1][2]</sup> . |
| <b>IC<sub>50</sub> &amp; Target</b> | ATR<br><150 pM (K <sub>i</sub> )  |
| <b>In Vivo</b>                      | In monotherapy efficacy studies Gartisertib shows tumor stasis to regression in tumor models with alternative lengthening of telomeres (ALT). In combination with PARP inhibitors, tumor regression could be observed in triple-negative breast cancer xenograft models <sup>[1]</sup> .              |

---

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

---

- [1]. Frank T. Zenke, et al. Abstract 369: Antitumor activity of M4344, a potent and selective ATR inhibitor, in monotherapy and combination therapy. *Experimental and Molecular Therapeutics*.
- [2]. Gorecki L, et al. Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy. *Pharmacol Ther.* 2020 Feb 26:107518.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA